Ann Richmond

Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity. Ann Richmond, PhD, Ingram Professor of Cancer Biology and professor of Pharmacology, is internationally known… Read More

Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity. Ann Richmond, PhD, Ingram Professor of Cancer Biology and professor of Pharmacology, is internationally known… Read More

By Kensey Bergdorf Ann Richmond In a continuation of previous work studying the role of chemokine receptor CXCR2 in immune cells published in Cancer Immunology Research, the lab of Ann Richmond, Ingram Professor of Cancer Biology and professor of pharmacology, has identified that same receptor as a regulator of melanoma… Read More

By Aran Sullivan Felysha Jenkins, Ph.D. During February—Black History Month—Basic Sciences community members participated in a 21-day Racial Equity Challenge. Felysha Jenkins, the Basic Sciences diversity, equity, and inclusion program manager, organized the challenge for the Basic Sciences community, using resources from the… Read More

L-R: Ann Richmond, Chi Yan By Wendy Bindeman Ann Richmond, professor of pharmacology, and Chi Yan, a research assistant professor in the Richmond lab, recently published a study showing that expression of a protein called CD40 can be used to predict response to immunotherapy in malignant melanoma. Read More

Many melanoma patients are treated with drugs called BRAF or MEK inhibitors that specifically target the mutant proteins created in cancerous tumors.  These inhibitors can block the tumors’ ability to grow and spread. According to Ann Richmond, Ingram Professor of Cancer Research and professor of pharmacology… Read More

Although targeted therapies have been developed for melanoma patients, tumor progression eventually results. Understanding characteristics of melanoma associated with treatment resistance is important for prolonging therapy effectiveness. In a retrospective study of patients treated with BRAF and/or MEK inhibitors, Chi Yan, PhD, Ann Richmond, PhD, and… Read More